Early insulin treatment in type 2 diabetes: ORIGINal sin or valuable choice as ORIGINal treatment? An open debate on the ORIGIN study results

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 22, Issue 12, 2012, Pages 1007-1012

  Bolli, G B ^a   Consoli, A ^b   Giaccari, A ^c  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Glargine; Impaired fasting glucose; Impaired glucose tolerance; Insulin treatment; ORIGIN; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLARGINE; INSULIN; LONG ACTING INSULIN;

CARDIOVASCULAR DISEASE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SHORT SURVEY;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84870442509     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2012.10.004     Document Type: Short Survey

References (24)

1. ODCC " Original sin" The Oxford dictionary of the Christian church 2005, Oxford University Press, Oxford. 3rd rev. ed. F.L. Cross, E.A. Livingstone (Eds.)
2. Brodd Jefferey World religions 2003, Saint Mary's Press, Winona, MN.
3. Catechism, U.S.Catholic Church Catechism of the Catholic church: with modifications from the EditioTypica 2003, Doubleday, New York. 2nd ed.
4. Weng J., Li Y., Xu W., Shi L., Zhang Q., Zhu D., et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicenter randomised parallel-group trial. Lancet 2008 May 24, 371(9626):1753-1760.
5. Bowker S.L., Yasui Y., Veugelers P., Johnson J.A. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 2010 Aug, 53(8):1631-1637.
6. Gerstein H.C., Bosch J., Dagenais G.R., Díaz R., Jung H., Maggioni A.P., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012 Jul 26, 367(4):319-328. ORIGIN Trial Investigators.
7. Bosch J., Gerstein H.C., Dagenais G.R., Díaz R., Dyal L., Jung H., et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012 Jul 26, 367(4):309-318. ORIGIN Trial Investigators.
8. Origin Trial Investigators, Gerstein H., Yusuf S., Riddle M.C., Ryden L., Bosch J. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008 Jan, 155(1):26-32.
9. Brunetti P., Muggeo M., Cattin L., Arcangeli A., Pozzilli P., Provenzano V., et al. Incidence of severe nocturnal hypoglycemia in patients with type 1 diabetes treated with insulin lispro or regular human insulin in addition to basal insulin glargine. Nutr Metab Cardiovasc Dis 2010 Sep, 20(7):519-526.
10. Giaccari A., Sorice G., Muscogiuri G. Glucose toxicity: the leading actor in the pathogenesis and clinical history of type 2 diabetes - mechanisms and potentials for treatment. Nutr Metab Cardiovasc Dis 2009 Jun, 19(5):365-377.
11. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012 Jun, 35(6):1364-1379. American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD)European Association for the Study of Diabetes (EASD).
12. UKPDS Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 Sep 12, 352(9131):837-853.
13. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., Buse J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 Jun 12, 358(24):2545-2559. Action to Control Cardiovascular Risk in Diabetes Study Group.
14. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 Jun 12, 358(24):2560-2572. ADVANCE Collaborative Group.
15. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009 Jan 8, 360(2):129-139. VADT Investigators.
16. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 Oct 9, 359(15):1577-1589.
17. Currie C.J., Johnson J.A. The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. Diabetes Obes Metab 2012 Jan, 14(1):1-4.
18. Gaede P., Lund-Andersen H., Parving H.H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008 Feb 7, 358(6):580-591.
19. Gale E.A. Insulin glargine and cancer: another side to the story?. Lancet 2009 Aug 15, 374(9689):521.
20. Boyle P., Koechlin A., Boniol M., Robertson C., Bolli G., Rosenstock J. Updated meta-analysis of cancer risk among users of insulin glargine. Diabetes 2012, 61(Suppl. 1):A345.
21. Bolli G.B., Hahn A., Schmidt R., Eisenblatter T., Dahmen R., Heise T., et al. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supra-therapeutic doses of glargine in subjects with Type 1 diabetes mellitus. Diabetes Care 2012 Dec, 35(12):2626-2630.
22. Lucidi P., Porcellati F., Rossetti P., Candeloro P., Marinelli Andreoli A., Cioli P., et al. Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with Type 2 diabetes mellitus. Diabetes Care 2012 Dec, 35(12):2647-2649.
23. Maedler K., Carr R.D., Bosco D., Zuellig R.A., Berney T., Donath M.Y. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005 Jan, 90(1):501-506.
24. Dandona P., Chaudhuri A., Ghanim H., Mohanty P. Proinflammatory effects of glucose and anti-inflammatory effect of insulin: relevance to cardiovascular disease. Am J Cardiol 2007 Feb 19, 99(4A):15B-26B.